Thomas Ramge – författare

Markets have long been acknowledged to be a superior mechanism for managing resources but until the advent of big data, they largely functioned better in theory than in practice. Now, as ideal markets are within reach because of vastly greater access to information, we are on the verge of a major disruption. As data becomes a more valuable asset than cash, the rules for surviving and thriving are changing.Reinventing Capitalism is a provocative look at how data is reinventing markets and, in so doing, is ushering in an era where the firm is no longer predominant. With richer and more comprehensive information about human wants and needs, an economy powered by data offers the possibility of increased abundance, equality, and resilience. The data-driven markets that will thrive in this environment are far better than firms at organizing human endeavors, meaning that finance driven capitalism is being displaced by its more efficient, moresustainable, and more democratic disruptor: data capitalism.

What if you could live not just longer, but healthier—and possibly forever? In his groundbreaking exploration of biotechnology, ethics, and the philosophy of very long lives, Thomas Ramge takes readers on a thought-provoking journey through the possibilities and consequences of radical life extension. Drawing on cutting-edge research in molecular biology, genetics, and AI-driven medicine, the book examines how humanity is on the brink of a revolution—one where aging may soon become a treatable condition. Through engaging thought experiments, such as choosing between three pills that extend life to 100, 200, or eternity, the book challenges our assumptions about mortality, identity, and purpose. Would centuries of life bring wisdom or existential despair? Could societies sustain themselves in a world where death is optional? And who would have access to these medical breakthroughs—everyone, or only the wealthy elite? Combining scientific rigor with philosophical depth, this book is a must-read for those fascinated by the intersection of technology, ethics, and the human condition. If the future of life itself is at stake, what will we choose?

What if you could live not just longer, but healthier—and possibly forever? In his groundbreaking exploration of biotechnology, ethics, and the philosophy of very long lives, Thomas Ramge takes readers on a thought-provoking journey through the possibilities and consequences of radical life extension. Drawing on cutting-edge research in molecular biology, genetics, and AI-driven medicine, the book examines how humanity is on the brink of a revolution—one where aging may soon become a treatable condition. Through engaging thought experiments, such as choosing between three pills that extend life to 100, 200, or eternity, the book challenges our assumptions about mortality, identity, and purpose. Would centuries of life bring wisdom or existential despair? Could societies sustain themselves in a world where death is optional? And who would have access to these medical breakthroughs—everyone, or only the wealthy elite? Combining scientific rigor with philosophical depth, this book is a must-read for those fascinated by the intersection of technology, ethics, and the human condition. If the future of life itself is at stake, what will we choose?

Eine gute Story macht ein Unternehmen greifbar. Sie regt die Fantasie an. Denn der Mensch liebt Geschichten. Bei Unternehmenstransaktionen ist eine spannende Equity Story ein mächtiger Hebel, den Wert zu erhöhen. Der Preis steigt, wenn Investoren, Investmentbanker und Business Angels die Equity Story im Wortsinn abkaufen. Umso erstaunlicher ist: Viele Verkäufer von Unternehmensanteilen verzichten darauf, die Mittel des Storytellings für ihre Zwecke zu nutzen.

Dabei gilt auch im Kontext von Mergers & Acquisitions, Private Equity und Venture Capital: Eine gute Equity Story ist mehr als glänzende Power Point-Präsentationen, optimistische Zahlungsströme und komplexe Excel-Sheets. Equity Storytelling ist kreatives Handwerk, verbunden mit analytisch-strategischer Grundkompetenz. Das Standardwerk für alle, die Unternehmen oder Unternehmensteile kaufen und verkaufen.